Results 11 to 20 of about 7,288 (241)

Modéliser mathématiquement la mucoviscidose [PDF]

open access: yesÉbullition(s) : le cahier illustré de la recherche
Le projet MucoReaDy vise à modéliser le transport du mucus dans les poumons pour évaluer son bon fonctionnement, en particulier chez les patients atteints de mucoviscidose.
P. Poncet   +9 more
semanticscholar   +2 more sources

Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programmeResearch in context [PDF]

open access: yesEClinicalMedicine
Summary: Background: The European Medicines Agency has recently expanded the label of elexacaftor-tezacaftor-ivacaftor (ETI) to all people with cystic fibrosis (pwCF) aged 2 years and older who have at least one non-Class I mutation in the cystic ...
Pierre-Régis Burgel   +8 more
doaj   +2 more sources

Rationally Designed InhA Inhibitors: A Comparative Anti-Tubercular Activity Study of Sulfonate Esters of Isoniazid Hydrazones and Their Structurally Flexible Benzyl Analogues. [PDF]

open access: yesChem Biol Drug Des
A comparative anti‐tubercular evaluation of sulfonate esters of isoniazid hydrazones and their structurally flexible benzyl analogues disclosed several potent compounds against Mycobacterium tuberculosis with the representative compound displaying an MIC of 0.078 μg/mL.
Kadima MG   +8 more
europepmc   +2 more sources

Rational Design and Antimycobacterial Evaluation of Aryl Sulfonamide-Linked Isoniazid Hydrazones Against Mycobacterium Tuberculosis. [PDF]

open access: yesChemMedChem
Molecular docking shows that ligands 8 (a–i) adopt a U‐shaped geometry in the InhA active site, enabling stronger interactions than 7 (j–r). Surprisingly, both sets display similar potency, indicating that factors like electronic effects or solvation also influence anti‐TB activity.
Kadima MG   +10 more
europepmc   +2 more sources

Dépistage néonatal de la mucoviscidose [PDF]

open access: yesmédecine/sciences, 2021
Le dépistage néonatal (DNN) de la mucoviscidose a permis une prise en charge multidisciplinaire très précoce des nourrissons et a amélioré le pronostic de cette maladie. Il a connu, en une vingtaine d’années, un développement international spectaculaire.
Anne Munck   +9 more
semanticscholar   +2 more sources

Improvement of iron status with elexacaftor tezacaftor ivacaftor therapy is associated with the correction of systemic inflammation and improvement of lung function: a one-year prospective study [PDF]

open access: yesScientific Reports
Iron deficiency (ID) is frequent in adult patients with cystic fibrosis (pwCF). The effect of elexacaftor-tezacaftor-ivacaftor (ETI) on iron metabolism has rarely been reported.
Hervé Lobbes   +5 more
doaj   +2 more sources

Mucoviscidose chez l’adulte

open access: yesRevue des Maladies Respiratoires Actualités, 2023
C. Belhaj   +5 more
openaire   +2 more sources

Manifestations digestives et hépatobiliaires des enfants atteints de mucoviscidose à Oran, Algérie [PDF]

open access: yesBatna Journal of Medical Sciences, 2021
Introduction. La mucoviscidose reste une affection potentiellement sévère, responsable d’une morbimortalité élevée dans notre pays en raison du retard diagnostique et de prise en charge des enfants vu l’absence de dépistage néonatal.
Nada Boutrid   +3 more
doaj   +1 more source

Nouveaux traitements pour la mucoviscidose

open access: yesPaediatrica, 2023
Avec une incidence de 1/3500, la mucoviscidose est la maladie autosomique-récessive potentiellement mortelle la plus fréquente dans la population caucasienne. Elle est causée par une mutation dans le gène Cystic Fibrosis Transmembrane Regulator (CFTR), à
Bettina Frauchiger   +1 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy